Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

54 results about "Solid organ transplantation" patented technology

Definition of Solid Organ Transplant. Solid Organ Transplant means live-donor kidney transplants and transplants of the following organs from cadaveric donors: kidney, pancreas, liver, intestines, heart and lung, but not the transplantation of stem cells, bone marrow, peripheral blood or cord blood.

Methods and compositions for evaluating graft survival in a solid organ transplant recipient

Methods are provided for evaluating a subject for graft survival, e.g., in terms of predicting graft survival, identifying the presence of a deleterious graft condition, such as CAN and DT, identifying the severity and class of acute rejection, etc, in a subject are provided. In practicing the subject methods, the expression of at least one gene in a sample from the subject, e.g., a blood or biopsy sample, is assayed, e.g., at the nucleic acid and / or protein level, to evaluate the subject. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Function Inhibitor of Effector Cell

InactiveUS20070270429A1Inhibit functioningBiocideOrganic chemistryAutoimmune conditionIslet cell transplantation
The present invention relates to a function inhibitor of an effector cell comprising a CCR5 antagonist. Since the function inhibitor of an effector cell comprising a CCR5 antagonist inhibits the function of effector cells which play an important role in formation of diseases and the like, it is effective for the prevention and / or treatment of, for example, a transplant rejection (e.g., rejection of a solid organ graft, rejection of islet cell transplantation in diabetes mellitus, graft-versus-host disease (GVHD), etc.), an autoimmune disease (e.g., arthritis, rheumatoid arthritis, multiple sclerosis, ulcerative colitis, etc.), an allergic disease (e.g., asthma, etc.), an ischemic disease (e.g., ischemia-reperfusion injury, etc.), cancer or a metastatic disease or the like.
Owner:ONO PHARMA CO LTD

HIF-1 Modulator Paint Formulation and Uses Thereof

Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +2

Non-invasive early detection of solid organ transplant rejection by quantitative analysis of mixtures by deep sequencing of HLA gene amplicons using next generation systems

The invention is a method of detecting or assessing solid organ graft (transplant) rejection by detecting donor-specific HLA alleles in a blood sample of a graft (transplant) recipient. The invention further comprises a method of detecting the presence of maternal cells in a blood sample of an offspring.
Owner:THE SCRIPPS RES INST +1

Methods of detecting cell-free DNA in biological samples

The present disclosure is directed to methods of detecting cell-free DNA (cfDNA) in biological samples and using it to quantify organ damage and identify pathogens. In some aspects, the biological samples are from patients who have undergone solid-organ transplantation. The disclosure is also directed to methods of detecting and analyzing methylation patterns in cell-free DNA from organ transplant patients to identify the presence of pathogens as well as quantify contributing tissue proportions as a measurement of the host response.
Owner:CORNELL UNIVERSITY

Method of treating diseases using kinase modulators

Provided herein are methods of modulating immune response, including methods of treating a cancer or an infection using a combination of kinase modulators and immunotherapy that promotes immune response. Also provided herein are methods of treating an autoimmune disease or graft-versus-host disease, and methods of reducing the risk of solid organ transplant rejection using a combination of kinase modulators and immunosuppressive therapy.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Method of immunomodulation

The present invention relates generally to a method for modulating the activity of cells of the immune system, including stimulator and responder cells and to agents useful therefor. More particularly, the present invention relates to a method for preventing or down-regulating one or more functional activities of stimulator and responder cells such as, respectively, antigen-presenting cells and lymphocytes inter alia. The present invention further provides antibodies, which interact specifically with epitopes present on the surface of antigen-presenting cells and lymphocytes, resulting in depletion, down-regulation or destruction of targeted antigen-presenting cells and lymphocytes in vivo or in vitro. The instant invention further provides a method for modulating an immune response in a subject and, in particular, for down-regulating the immuno-activity of an allogeneic immuno-competent graft and / or the immune response of a recipient of a solid organ transplant. The ability to modulate stimulator and responder cell immuno-activity may be useful, inter alia, in a range of immuno-therapeutic and immuno-prophylactic treatments that benefit from immune suppression.
Owner:THE OF THE TRUSTEES OF THE SISTERS OF MERCY & QUEENSLAND

Mobilization and collection of peripheral blood hematopoietic stem cells from deceased donors

This invention describes new methods for the mobilization of human cells such as hematopoietic stem cells in bone marrow, and the subsequent collection of such cells from the peripheral blood of deceased donors. These methods produce quantities of hematopoietic stem cells that can be used in a multitude of possible applications without harming the deceased donor or the recovery of the deceased donor's organs for solid organ transplantation. The methods involve the administration of one or more mobilizing agents to mobilize bone marrow cells into the peripheral blood cells followed by the collection of cells via apheresis.
Owner:RGT UNIV OF CALIFORNIA

Methods of Treating CMV Retinitis by T Cell Therapy

Disclosed herein are methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with HIV or has been the recipient of a solid organ transplant.
Owner:CORNELL UNIVERSITY +1

Chimeric antigen receptor targeting HLA-A, coding gene, CAR-Tregs cell and preparation method and application thereof

The invention discloses a chimeric antigen receptor targeting HLA-A, a coding gene, a recombinant expression vector, a CAR-Tregs cell and a preparation method and application thereof. The chimeric antigen receptor comprises a signal peptide, an antigen binding structural domain, a hinge region, a transmembrane region, a costimulatory factor and an intracellular signal transduction domain. The antigen binding domain is a binding structural domain of an anti-HLA-A11 antibody or an anti-HLA-A33 antibody, and the CAR-Tregs cell is a Treg cell modified by a chimeric antigen receptor targeting HLA-A11 or HLA-A33, can inhibit specific immune response, and can be used for inhibiting rejection reaction after a solid organ transplantation operation.
Owner:CHENGDU SHIKANGMEI BIOTECHNOLOGY CO LTD

Non-invasive early detection of solid organ transplant rejection by quantitative analysis of HLA gene amplicons

The invention is a method of detecting or assessing solid organ graft (transplant) rejection and acute dysfunction—no rejection condition by detecting donor-specific HLA alleles in a blood sample of a graft (transplant) recipient.
Owner:THE SCRIPPS RES INST A PUBLIC BENEFIT NOT FOR PROFIT RES INST +1

Chimeric antigen receptor targeting HLA-A, encoding gene, CAR-Tregs cells, and preparation method and application of CAR-Tregs cells

The invention discloses a chimeric antigen receptor targeting HLA-A, an encoding gene, a recombinant expression vector, CAR-Tregs cells, and a preparation method and application of the CAR-Tregs cells. The chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a hinge region, a transmembrane region, a co-stimulatory factor and an intracellular signal transduction domain;the antigen binding domain is a binding domain of an anti-HLA-A11 antibody or an anti-HLA-A33 antibody; the CAR-Tregs cells disclosed by the invention are Treg cells modified by the chimeric antigen receptor targeting HAL-A11 or HLA-A33, can inhibit specific immunoreaction and can be used for inhibition from solid organ transplantation postoperative rejection reaction.
Owner:成都仕康美生物科技有限公司

Methods of Treating Diseases Using Kinase Modulators

Provided herein are methods of modulating immune response, including methods of treating a cancer or an infection using a combination of kinase modulators and immunotherapy that promotes immune response. Also provided herein are methods of treating an autoimmune disease or graft-versus-host disease, and methods of reducing the risk of solid organ transplant rejection using a combination of kinase modulators and immunosuppressive therapy.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Adoptive t-cell therapy for cmv infection and cmv-associated diseases

Provided herein are immunogenic polypeptides, compositions, and methods related to the development of CMV-specific prophylactic and / or therapeutic immunotherapy based on T cell epitopes (e.g., CMV epitopes) that are recognized by cytotoxic T cells (CTLs) and can be employed in the prevention and / or treatment of CMV infection, reactivation, and / or disease (e.g., CMV-associated end organ disease), especially in solid organ transplant recipients.
Owner:COUNCIL OF THE QUEENSLAND INST OF MEDICAL RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products